Core Viewpoint - BioAtla, Inc. has announced a registered direct offering of 9,679,158 shares of common stock, aiming to raise approximately $9.2 million to fund its research and development efforts, particularly for its mid-stage clinical programs [1][4]. Group 1: Offering Details - The offering includes warrants to purchase one share of common stock at an exercise price of $1.19 per share, with a combined offering price of $0.9520 per share and warrant [1]. - The closing of the offering is expected to occur on or about December 20, 2024, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will be used to fund research and development, including key inflection points for the mid-stage clinical TCell Engager (TCE) and Antibody Drug Conjugate (ADC) programs [4]. - Specific programs mentioned include BA3182 (Phase 1 data expected in 2Q25) and mecbotamab vedotin (Phase 2B data expected in 1H26) [4]. Group 3: Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][10]. - The company has two first-in-class CAB programs in Phase 2 clinical testing and a dual CAB bispecific T-cell engager antibody in Phase 1 development [10]. - BioAtla holds extensive patent coverage for its CAB technology, with over 780 active patent matters [10].

Core Insights - BioAtla, Inc. presented data indicating improved one-year overall survival (OS) for patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) treated with Mecbotamab Vedotin (Mec-V) compared to those with wild-type KRAS (wtKRAS) [1][2] - The one-year OS was reported at 58% for mKRAS patients versus 23% for wtKRAS patients, suggesting Mec-V's potential as a promising treatment option across all KRAS mutation variants [2][3] - A randomized trial of Mec-V in patients with treatment-refractory mKRAS NSCLC is planned for initiation in 2025 based on these findings [2] Company Overview - BioAtla, Inc. is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][4] - The company has two first-in-class CAB programs currently in Phase 2 clinical testing: Mecbotamab Vedotin targeting AXL and ozuriftamab vedotin targeting ROR2 [5] - BioAtla has extensive patent coverage for its CAB technology, with over 780 active patent matters, including more than 500 issued patents [5] Clinical Trial Data - The Phase 2 trial of Mec-V enrolled 78 patients, with 30.7% having mKRAS NSCLC [3] - Among the 21 efficacy-evaluable patients with mKRAS NSCLC, the overall response rate (ORR) was 28.6%, with notable antitumor activity observed across 9 different mKRAS variants [3] - Treatment with Mec-V was well tolerated, showing a manageable safety profile without new safety signals [3] AXL Expression and KRAS Mutation - A strong correlation was confirmed between KRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring any KRAS mutation showing high AXL expression [2][3] - Among the mKRAS G12C variant subset, 81.8% exhibited high AXL expression, reinforcing the relevance of AXL as a therapeutic target [3]

Core Insights - BioAtla, Inc. presented promising data on Mecbotamab Vedotin (Mec-V) for treatment-refractory non-small cell lung cancer (NSCLC) with mutated KRAS (mKRAS), showing a one-year overall survival (OS) of 58% compared to 23% for wild-type KRAS (wtKRAS) patients [1][3][4] Group 1: Clinical Trial Results - The Phase 2 trial of Mec-V included 78 patients, with 30.7% having mKRAS NSCLC [4] - Among patients with mKRAS NSCLC, the median OS was not yet reached, while the median OS for wtKRAS was 8.7 months [4] - The overall response rate (ORR) for mKRAS NSCLC patients was 28.6%, with notable antitumor activity across 9 different mKRAS variants [4] Group 2: Mechanism and Targeting - Mec-V is a conditionally active antibody-drug conjugate targeting AXL, which is highly expressed in mKRAS NSCLC [6][4] - A strong correlation was confirmed between mKRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring KRAS mutations showing high AXL expression [3][4] Group 3: Future Plans - BioAtla plans to initiate a randomized trial of Mec-V in 2025 for patients with treatment-refractory mKRAS NSCLC based on the encouraging findings [3][4] - The company has received Orphan Drug Designation from the FDA for Mec-V in treating soft tissue sarcoma, indicating its potential across multiple solid tumor indications [6]

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHN – Evalstotug ...

BioAtla, Inc. (NASDAQ: BCAB ) develops innovative cancer treatments with its proprietary Conditionally Active Biologics [CAB] platform. This technology allows for precise targeting of disease tissues while minimizing harm to healthy cells. This is a key benefit that typicalMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a ...

The cancer-focused microcap BioAtla, Inc. (NASDAQ: BCAB ) is a company I first covered back in May , highlighting the fresh air brought to their pipeline by the likes of Janux I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. Analyst's Di ...

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title: Updated results from a phase ...

When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice. His hedge fund, Scion Asset Management, acquired 633,959 shares of BioAtla (NASDAQ: BCAB) for $1.37 each during the second quarter, making 1.65% of his portfolioBioAtla shares started to move upward, finishing Monday at $1.76 and rising 6.81% pre-market on Tuesday, October 1st, to $1.88, suggesting growing confidence in the company’s future, particularly with today’s ...